Why the study?
What is the quantitative relationship between angiotensin converting enzyme activity in human serum and the concentration of the MK-421 active diacid metabolite in vitro and in vivo?
What is the quantitative relationship between angiotensin converting enzyme activity in human serum and the concentration of the MK-421 active diacid metabolite in vitro and in vivo?
The active diacid metabolite of MK-421 demonstrates potent inhibition of serum angiotensin converting enzyme activity with similar dose-response characteristics in vitro and after single in vivo doses.
Answers are grounded in this paper and cite their sources.
Potent in vitro ACE inhibition by MK-421 diacid supports further development; chronic effects and clinical translation remain uncertain.
Quantitative relationships between angiotensin converting enzyme activity in human serum and concentration of an enzyme inhibitor, the active diacid metabolite of MK-421 [N-(S-1-carbethoxy-3-phenylpropyl)-S-alanyl-S-proline maleate], were defined. Dose-response curves were generated in vitro by adding the diacid metabolite (DM) to serum (ID50 = to 6x10-9 M); l0-15% of initial activity was nonsuppressible. DM an converting enzyme activity were also measured in serum from hypertensive subjects receiving oral MK-421. The dose-response curve for serum samples following single doses of MK-421 (ID50 = 6x10-9M), was similar to curves generated in vitro while the curve for sample following chronic therapy suggested a small decrease in inhibitory potency.
No takes yet. Share an insight, caveat, or question.
Swanson et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: